Release
2024/04/18
Osaka, Japan, April 18, 2024 - Shionogi & Co., Ltd. (Head Office: Osaka; Chief Executice Officer: Isao Teshirogi, Ph.D.) announced that we completed cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act effective on April 17, 2024, as resolved at the meeting of the Board of Directors held on July 31, 2023.
1. Class of shares cancelled Common stock of the Company
2. Total number of shares cancelled 10,842,100 shares
(3.53% of total outstanding shares before cancellation)
3. Date of cancellation April 17, 2024
(Reference)
1. Total number of shares issued (after cancellation) 296,544,065 shares
2. Number of treasury shares (after cancellation) 10,052,610 shares
3. Details of acquisition of treasury stock based on the resolution at the meeting of the Board of Directors held
on July 31, 2023
(1) Class of shares to be acquired Common stock of the Company
(2) Total number of shares to be acquired 12,500,000 shares (maximum)
(4.2% of total outstanding shares [excluding treasury stock])
(3) Total amount of acquisition cost 75 billion yen (maximum)
(4) Period of acquisition (planned) From August 1, 2023 to March 31, 2024
4. The accumulative number and value of own shares acquired based on 3 above
(1) Total number of shares acquired 10,842,100 shares
(2) Total value of shares acquired 74,999,218,753 yen
5. Details of cancellation of treasury stock based on the resolution at the meeting of the Board of Directors held on July 31, 2023
(1) Class of shares to be cancelled Common stock of the Company
(2) Number of shares to be cancelled Total number of treasury shares acquired based on 3 above
(3) Scheduled date of cancellation April 17, 2024
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html